Court Backs Employer Plan that Refused to Cover GLP-1 Weight-Loss Drug

Why It Matters

The decision clarifies that ERISA plans are enforced strictly according to their written exclusions, limiting employee challenges based on medical necessity and placing the onus on employers to redesign benefits if they want to include GLP‑1 treatments.

Key Takeaways

• Court upheld plan’s “weight‑loss” drug exclusion for Zepbound
• FDA approval for sleep apnea didn’t override plan language
• ERISA fiduciary duty claim dismissed; plan administrators followed documents
• Employers must revise plan documents to cover GLP‑1 drugs if desired
• Mounjaro coverage differs because it’s approved for diabetes, not weight loss

Pulse Analysis

The surge in GLP‑1 medications, driven by their effectiveness for obesity, diabetes, and now sleep apnea, has put employer‑sponsored health plans under pressure to expand coverage. While employees argue that FDA approvals create a medical necessity, the legal framework governing employee benefits—ERISA—prioritizes the precise language of the plan document. This case illustrates how courts will not reinterpret exclusions to accommodate new indications, leaving plan sponsors to decide whether to broaden formularies or risk costly litigation.

In the Washington case, the judge focused on the plan’s rider that bars "prescription drugs for weight loss," a category that Zepbound falls under despite its FDA clearance for sleep apnea. The court also dismissed the fiduciary‑duty claim, noting that administrators who act in accordance with the plan’s terms meet their ERISA obligations. The distinction between Zepbound and Mounjaro—covered for diabetes but not for weight loss—highlights how drug approvals and therapeutic overlap do not automatically translate into uniform coverage. Employers must therefore scrutinize their benefit documents and ensure that exclusions align with corporate health‑cost strategies.

For HR and benefits leaders, the ruling serves as a practical checklist: review plan language, update drug riders, and communicate any changes to employees. Adding GLP‑1 drugs to a formulary can increase pharmacy spend, but the cost may be offset by reduced long‑term health expenses linked to obesity‑related conditions. As more GLP‑1 therapies gain FDA approvals, employers will need to balance clinical value against budget impact, possibly leveraging tiered copays or prior‑authorization protocols. Proactive plan redesign, rather than reactive litigation, will become the more efficient path forward.